NNC2215
NNC2215 is a bioengineered glucose-sensitive insulin. The drug is designed by a team of Novo Nordisk researchers.[1]
NNC2215 can sense the glucose concentration in blood. The protein's sensitivity is reduced when the glucose concentration is low, thus reducing the risk of hypoglycemia.[2] In addition, it can effectively cover the risk of fluctuations of blood sugar levels.
The study was published in the scientific journal Nature on October 16, 2024.[3] This study demonstrated the ability of protein engineering in future medicine and a huge advancement in treatment capabilities.
History
A glucose-sensitive treatment method for diabetes has long been pursued by science since 1979.[4] Such a protein is expected to solve the problem of fluctuations of blood sugar levels. For diabetes patients, skipping meals alone could lead to hypoglycemia, which is a common complication that could cause loss of consciousness or seizures.[5]
There are several attempts to create such a medicine with various levels of success.[6][7]
See also
References
- ↑ PhD, Jonathan D. Grinstein (2024-10-21). "Novo Nordisk Researchers Engineer Glucose-Sensitive Insulin Switch". Inside Precision Medicine. Retrieved 2025-01-01.
- ↑ Kwon, Diana (2024-10-16). "'Smart' insulin prevents diabetic highs — and deadly lows". Nature. doi:10.1038/d41586-024-03357-7. PMID 39414970 Check
|pmid=value (help). - ↑ Hoeg-Jensen, Thomas; Kruse, Thomas; Brand, Christian L.; Sturis, Jeppe; Fledelius, Christian; Nielsen, Peter K.; Nishimura, Erica; Madsen, Alice R.; Lykke, Lennart; Halskov, Kim S.; Koščová, Simona; Kotek, Vladislav; Davis, Anthony P.; Tromans, Robert A.; Tomsett, Michael (16 October 2024). "Glucose-sensitive insulin with attenuation of hypoglycaemia". Nature. 634 (8035): 944–951. Bibcode:2024Natur.634..944H. doi:10.1038/s41586-024-08042-3. ISSN 1476-4687. PMC 11499270 Check
|pmc=value (help). PMID 39415004 Check|pmid=value (help). - ↑ Brownlee, Michael; Cerami, Anthony (1979-12-07). "A Glucose-Controlled Insulin-Delivery System: Semisynthetic Insulin Bound to Lectin". Science. 206 (4423): 1190–1191. doi:10.1126/science.505005.
- ↑ "Low Blood Glucose (Hypoglycemia) - NIDDK". National Institute of Diabetes and Digestive and Kidney Diseases. Retrieved 2025-01-01.
- ↑ Jarosinski, Mark A; Chen, Yen-Shan; Varas, Nicolás; Dhayalan, Balamurugan; Chatterjee, Deepak; Weiss, Michael A (2022-04-01). "New Horizons: Next-Generation Insulin Analogues: Structural Principles and Clinical Goals". The Journal of Clinical Endocrinology & Metabolism. 107 (4): 909–928. doi:10.1210/clinem/dgab849. ISSN 0021-972X.
- ↑ Liu, Yun; Wang, Shiqi; Wang, Zejun; Yu, Jicheng; Wang, Jinqiang; Buse, John B.; Gu, Zhen (2024-06-10). "Recent Progress in Glucose-Responsive Insulin". Diabetes. 73 (9): 1377–1388. doi:10.2337/dbi23-0028. ISSN 0012-1797.
 | This pharmacology-related article is a stub. You can help EverybodyWiki by expanding it. |
This article "NNC2215" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:NNC2215. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
